Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.31 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.31 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.31 |
| ▸ | OGA | O60502 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25029033 | 0.81 | PIK3CA (0.33) | KDM4EPIK3CAPIK3CBPIK3CGOGA | |
| SCHEMBL29363497 | 0.81 | PIK3CA (0.33) | KDM4EPIK3CAPIK3CBPIK3CGOGA | |
| SCHEMBL19200105 | 0.79 | OGA (0.33) | PIK3CAOGA | |
| SCHEMBL24224470 | 0.79 | TRPV1 (0.35) | KDM4EPIK3CAPIK3CBPIK3CGOGA | |
| SCHEMBL24156629 | 0.77 | NOTUM (0.48) | — | |
| SCHEMBL17807792 | 0.74 | PIK3CA (0.33) | PIK3CA | |
| SCHEMBL17807780 | 0.74 | PIK3R1 (0.33) | KDM4EPIK3CA | |
| SCHEMBL15221563 | 0.73 | KDM4E (0.37) | KDM4EPIK3CAOGA | |
| SCHEMBL18237771 | 0.73 | KDM4E (0.31) | KDM4EOGA | |
| SCHEMBL16708458 | 0.73 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230159512-A1 | COMPOUNDS AS GLP-1R AGONISTS | TERNS PHARMACEUTICALS, INC. | 2023-05-25 | — | — | US | disclosed |
| US-10208061-B2 | Tetrahydro[1,8]naphthyridine sulfonamide and related compounds for use as agonists of RORγ and the treatment of disease | LYCERA CORPORATION (US) | 2019-02-19 | — | — | US | disclosed |
| US-10010556-B2 | Bicyclic bromodomain inhibitors | ZENITH EPIGENETICS LTD. (CA) | 2018-07-03 | — | — | US | disclosed |
| US-20180179224-A1 | Tetrahydro[1,8]naphthyridine Sulfonamide And Related Compounds for Use as Agonists of RORy and the Treatment of Disease | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2018-06-28 | — | — | US | disclosed |
| US-20180179224-A1 | Tetrahydro[1,8]naphthyridine Sulfonamide And Related Compounds for Use as Agonists of RORy and the Treatment of Disease | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2018-06-28 | — | — | US | disclosed |
| US-20180161337-A1 | NOVEL BICYCLIC BROMODOMAIN INHIBITORS | RVX THERAPEUTICS INC. (CA) | 2018-06-14 | — | — | US | disclosed |
| US-9802958-B2 | Tetrahydro[1,8]naphthyridine sulfonamide and related compounds for use as agonists of RORy and the treatment of disease | LYCERA CORPORATION (US) | 2017-10-31 | — | — | US | disclosed |
| US-20170216301-A1 | NOVEL BICYCLIC BROMODOMAIN INHIBITORS | ZENITH EPIGENETICS LTD. | 2017-08-03 | — | — | US | disclosed |
| US-9663520-B2 | Bicyclic bromodomain inhibitors | ZENITH EPIGENETICS LTD. (CA) | 2017-05-30 | — | — | US | disclosed |
| US-20170007686-A1 | Adoptive Cellular Therapy Using an Agonist of Retinoic Acid Receptor-Related Orphan Receptor Gamma & Related Therapeutic Methods | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2017-01-12 | — | — | US | disclosed |
| US-20160318951-A1 | Tetrahydro[1,8]naphthyridine Sulfonamide And Related Compounds for Use as Agonists of RORy and the Treatment of Disease | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2016-11-03 | — | — | US | disclosed |
| US-9394315-B2 | Tetrahydro[1,8]naphthyridine sulfonamide and related compounds for use as agonists of RORγ and the treatment of disease | LYCERA CORPORATION (US) | 2016-07-19 | — | — | US | disclosed |
| US-20160159801-A1 | NOVEL BICYCLIC BROMODOMAIN INHIBITORS | ZENITH EPIGENETICS CORP. | 2016-06-09 | — | — | US | disclosed |
| US-20150133437-A1 | Tetrahydro[1,8]naphthyridine Sulfonamide and Related Compounds for Use as Agonists of RORy and the Treatment of Disease | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2015-05-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10010556-B2 | Bicyclic bromodomain inhibitors | BRD4, BRD3, BRD2 | KDM4E 410/4885PIK3CA 2238/4885PIK3CB 1256/4885 |
| US-20180161337-A1 | NOVEL BICYCLIC BROMODOMAIN INHIBITORS | BRD4, BRD3, BRD2 | KDM4E 367/4885PIK3CA 2280/4885PIK3CB 1160/4885 |
| US-20230159512-A1 | COMPOUNDS AS GLP-1R AGONISTS | GLP1R, GIPR, GCGR | KDM4E 4341/4885PIK3CA 1557/4885PIK3CB 1997/4885 |
| US-20150133437-A1 | Tetrahydro[1,8]naphthyridine Sulfonamide and Related Compounds for Use as Agonists of RORy and the Treatment of Disease | RORC, RORA, RORB | KDM4E 2721/4885PIK3CA 2593/4885PIK3CB 3801/4885 |
| US-20160318951-A1 | Tetrahydro[1,8]naphthyridine Sulfonamide And Related Compounds for Use as Agonists of RORy and the Treatment of Disease | RORA, RORC, RORB | KDM4E 2661/4885PIK3CA 2266/4885PIK3CB 3656/4885 |
| US-20170007686-A1 | Adoptive Cellular Therapy Using an Agonist of Retinoic Acid Receptor-Related Orphan Receptor Gamma & Related Therapeutic Methods | RORC, RORA, RORB | KDM4E 4156/4885PIK3CA 3451/4885PIK3CB 4265/4885 |
| US-20170216301-A1 | NOVEL BICYCLIC BROMODOMAIN INHIBITORS | BRD4, BRD3, BRD2 | KDM4E 367/4885PIK3CA 2280/4885PIK3CB 1160/4885 |
| US-20160159801-A1 | NOVEL BICYCLIC BROMODOMAIN INHIBITORS | BRD4, BRD3, BRD2 | KDM4E 367/4885PIK3CA 2280/4885PIK3CB 1160/4885 |
| US-20180179224-A1 | Tetrahydro[1,8]naphthyridine Sulfonamide And Related Compounds for Use as Agonists of RORy and the Treatment of Disease | RORA, RORC, RORB | KDM4E 2751/4885PIK3CA 2395/4885PIK3CB 3529/4885 |
| US-10208061-B2 | Tetrahydro[1,8]naphthyridine sulfonamide and related compounds for use as agonists of RORγ and the treatment of disease | RORC, RORA, RORB | KDM4E 2906/4885PIK3CA 1868/4885PIK3CB 3600/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.